HORIZON PHARMACEUTICAL LLC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | |
|---|---|---|---|---|---|---|
| Revenue | $94.2M | $69.5M | $16.9M | $0 | $0 | $0 |
| Operating income | −$48.5M | −$40.0M | −$51.9M | −$36.2M | −$21.0M | −$13.1M |
| Net income | −$19.7M | −$14.9M | −$69.4M | −$14.0M | −$11.4M | −$10.1M |
| Total assets | $423.3M | $189.1M | $108.7M | $68.1M | $22.6M | — |
| Total liabilities | $306.2M | $140.1M | $80.2M | $48.2M | $26.7M | — |
| Equity | $117.2M | $48.9M | $28.6M | $19.9M | −$4.1M | $6.8M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 69.1M | 62.5M | 61.6M | 51.8M | 35.6M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- −51.4%
- Net margin
- −20.9%
- Return on equity
- −16.8%
- Return on assets
- −4.7%
- Return on capital (ROCE)
- −12.6%
- Liabilities / assets
- 72.3%
- Debt / equity
- 2.61×
- Book value / share
- $1.69
- Revenue growth (YoY)
- 35.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- -0.67distress
- Accruals / assets
- 5.8%moderate
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- PENNSAIDJan 16, 2014
- PROCYSBIApr 30, 2013
- RAYOSJul 26, 2012
- DUEXISApr 23, 2011
- VIMOVOApr 30, 2010
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Bruhn Suzanne LouiseDirector | Oct 24, 2016 | U | 48,437 | $9.00 |
| Gemayel GeorgesDirector | Oct 24, 2016 | U | 2,092 | $9.00 |
| Happel DavidOfficer — Chief Commercial Officer | Oct 24, 2016 | U | 8,934 | $9.00 |
| Smith Michael POfficer — Chief Financial Officer | Oct 25, 2016 | D | 22,607 | $9.00 |
| Gould Ashley C.Officer — Chief Legal Officer | Oct 24, 2016 | U | 9,286 | $9.00 |
| Lapointe Anthony GreggDirector | Oct 24, 2016 | U | 2,092 | $9.00 |
| Anderson RaymondDirector | Oct 24, 2016 | U | 6,695 | $9.00 |
| Smith JulieOfficer — President and CEO | Oct 24, 2016 | U | 45,759 | $9.00 |
| Keltner LlewDirector | Oct 24, 2016 | U | 6,695 | $9.00 |
| Franklin Richard LDirector | Oct 24, 2016 | U | 6,695 | $9.00 |
| Starr Christopher MDirector | Oct 24, 2016 | U | 706,065 | $9.00 |
| Polu Krishna ROfficer — Chief Medical Officer | Oct 25, 2016 | D | 23,781 | $9.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Modified shareholder rights · Amended charter or bylawsOct 31, 2016
- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 25, 2016
- Director / officer changeOct 19, 2016
- Entered a material agreement · Terminated a material agreementOct 11, 2016
- Entered a material agreement · Director / officer change · Amended charter or bylaws · Regulation FD disclosureSep 12, 2016
- Results of operationsAug 4, 2016
- Terminated a material agreementJul 7, 2016
- Other material eventMay 27, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.